Payment overview · 2025
General Payments
$882.61
39 reported records · 12 companies
Healthcare provider profile · identity verified
Gerold Noel Sibanda, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1063520591
Verified facts
What the public records show
CMS Open Payments records show Gerold Noel Sibanda, MD received $882.61 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $259.38 | 29.4% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $149.90 | 17.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.88 | 16.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.94 | 12.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.02 | 7.8% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $37.07 | 4.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.66 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.86 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.91 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.26 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.06 | 1.8% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.67 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $882.61 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $224.11 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $205.42 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $205.42 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $149.90 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.35 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.50 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.46 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $62.89 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 154 |
| Tramadol Hcl | Tramadol Hcl | 277 | 81 |
| Gabapentin | Gabapentin | 236 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 76 |
| Omeprazole | Omeprazole | 202 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 57 |
| Carvedilol | Carvedilol | 178 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 63 |
| Losartan Potassium | Losartan Potassium | 172 | 53 |
| Famotidine | Famotidine | 168 | 46 |
| Metformin Hcl Er | Metformin Hcl | 163 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 48 |
| Montelukast Sodium | Montelukast Sodium | 142 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 42 |
| Potassium Chloride | Potassium Chloride | 119 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 31 |
| Meloxicam | Meloxicam | 105 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 102 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 24 |
| Naproxen | Naproxen | 97 | 26 |
| Trulicity | Dulaglutide | 96 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 31 |
| Allopurinol | Allopurinol | 85 | 35 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 83 | 22 |
| Ibuprofen | Ibuprofen | 80 | 24 |
| Metformin Hcl | Metformin Hcl | 78 | 23 |
| Ozempic | Semaglutide | 77 | 11 |
| Simvastatin | Simvastatin | 75 | 20 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 74 | 21 |
| Temazepam | Temazepam | 73 | 16 |
| Lisinopril | Lisinopril | 72 | 23 |
| Clonazepam | Clonazepam | 67 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 24 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Alendronate Sodium | Alendronate Sodium | 63 | 24 |
| Nabumetone | Nabumetone | 61 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 17 |
| Linzess | Linaclotide | 59 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 14 |
| Alprazolam | Alprazolam | 41 | 11 |
| Telmisartan | Telmisartan | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Eliquis | Apixaban | 38 | 11 |
| Furosemide | Furosemide | 38 | 14 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Sertraline Hcl | Sertraline Hcl | 30 | 11 |
| Azithromycin | Azithromycin | 28 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | 11 |
| Prednisone | Prednisone | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Baclofen | Baclofen | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $882.61 · 39 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KRYSTEXXA, MOUNJARO, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TOLMETIN SODIUM, TRELEGY ELLIPTA, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error